Last updated: 2026-10-07 02:58:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
SAB Biotherapeutics, Inc. (SABS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.94, with a market capitalization of $271.14M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.06 to $5.15. This page covers its latest market performance, valuation, price trends and company information.
$271.14M | |
$3.12 | |
$120.90 | |
$1.00 | |
$3.10 | |
615.43K | |
493.25K | |
-- | |
$5.15 | |
$2.06 | |
-- | |
-- |
SAB Biotherapeutics, Inc. (SABS) last closed at $3.10 as of 2026-10-06 23:56:00, unchanged from the previous close of $3.10.
During the latest regular trading session, SABS traded between $1.00 and $120.90, with a volume of 615.43K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, SAB Biotherapeutics, Inc. (SABS) moved from $3.29 to $2.94, representing a decline of 10.76% ($0.35).
The stock traded between $2.86 and $3.49 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 914.62 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 28.5%
SABS is currently trading at $2.94, placing it 28.5% of the way from its 52-week low of $2.06 to its 52-week high of $5.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 86 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SAB Biotherapeutics, Inc. (SABS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.